daclizumab
information and resources from the National Cancer Institute
NCI Thesaurus | daclizumab
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. NCI Thesaurus | daclizumab
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.
|
|
|
|
news articles
Roche, Protein Design Labs expand partnership on transplant drug ... Nov 1, 2005
Forbes ZURICH (AFX) - Roche Holding AG said it and Protein Design Labs are expanding their existing development partnership for transplant drug Daclizumab in a deal ...
Roche and Protein Design Labs to jointly develop daclizumab in ... Nov 1, 2005
PharmaLive.com (press release), ...(PDL) (NASDAQ: PDLI) today announced an expansion to their partnership to co-develop and commercialize daclizumab for organ transplant patients on long-term ...
Roche and Protein Design Labs to Jointly Develop Daclizumab in ... Nov 1, 2005
PharmaLive.com (press release), ...(PDL) today announced an expansion to their partnership to co-develop and commercialize daclizumab for organ transplant patients on long-term, maintenance ...
Roche and Protein Design Labs to jointly develop daclizumab in ... Nov 1, 2005
Biotech Intelligence (press release), Roche and Protein Design Labs, Inc. (PDL) (NASDAQ: PDLI) today announced an expansion to their partnership to co-develop and commercialize daclizumab for organ ...
NEWS RELEASE Nov 2, 2005
Financial News USA (press release), Roche and Protein Design Labs to Jointly Develop Daclizumab and Cell Therapeutics, Inc. Announces $82 Million in Convertible Senior Notes Offering. ...
Steroid-Free Immunosuppression After Liver Transplant Reduces ... Nov 15, 2005
DG News ...and the corticosteroid prednisone (arm 1); tacrolimus, prednisone and CellCept (arm 2); tacrolimus, CellCept and 3-dose daclizumab, an immunosuppressive ...
PDL lands $10M under expanded Roche partnership Nov 1, 2005
East Bay Business Times, Roche(OTCPK: RHHBY) currently market's PDL's daclizumab as Zenapax for induction transplant therapy. The new agreement is to develop ...
Amid big losses, Protein Design lands $10M Roche deal Nov 1, 2005
San Francisco Business Times, Roche sells Protein Design's daclizumab as Zenapax for induction transplant therapy. The new deal is to develop daclizumab for organ ...
Five9 talks call centers with Philippine president Nov 1, 2005
San Jose Mercury News, The companies are expanding a partnership to further develop the drug, called daclizumab, or Zenapax. As part of the development ...
Biogen Idec Reports Third Quarter 2005 Results Oct 26, 2005
Business Wire (press release), The agreement provides for shared development and commercialization of daclizumab in MS and indications other than transplant and respiratory diseases, and for ...
PDL Announces Third Quarter 2005 Financial Results Nov 1, 2005
PR Newswire (press release), ...and ESP Pharma and Retavase acquisitions and the re-acquisition of rights to manufacture and market Zenapax(R) (daclizumab) in 2003, and stock-based ...
(PRN) - TXU Corp. Results Reflect Benefits of Restructuring ... Nov 1, 2005
Bolsamania.com, Trends ... [+. PRN) - Roche and Protein Design Labs to Jointly Develop Daclizumab in Transplant Maintenance Therapy ... [+. PRN ...
|
|
